CerS2 ko in vivo reduces pro-inflammatory ceramides and improves doxorubicin mediated cardiotoxicity
Tom Kretzschmar(Jena University Hospital), P. Christian Schulze(Temple College), Sándor Nietzsche(Schiller International University), Martin Westermann(Schiller International University), K Gruen(Jena University Hospital), Tobias Mueller(University of Würzburg), Markus H. Graeler(Jena University Hospital), Mohamed M. Bekhite(Jena University Hospital)
Cited by 2
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2023|2.2k